vs
ARTIVION, INC.（AORT）与3M（MMM）财务数据对比。点击上方公司名可切换其他公司
3M的季度营收约是ARTIVION, INC.的52.0倍（$6.0B vs $116.0M）。3M净利率更高（10.8% vs 2.1%，领先8.7%）。ARTIVION, INC.同比增速更快（19.2% vs 1.3%）。3M自由现金流更多（$2.0B vs $-7.9M）。过去两年ARTIVION, INC.的营收复合增速更高（9.1% vs -1.8%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
3M是美国知名跨国综合企业，业务覆盖工业、劳动者安全防护、消费品等多个领域，总部位于圣保罗郊区的枫木市。公司现有超6万款产品，涵盖胶粘剂、研磨材料、防火防护产品、个人防护装备、窗膜、车漆保护膜、电子连接绝缘材料、汽车养护产品、光学膜等品类。
AORT vs MMM — 直观对比
营收规模更大
MMM
是对方的52.0倍
$116.0M
营收增速更快
AORT
高出17.9%
1.3%
净利率更高
MMM
高出8.7%
2.1%
自由现金流更多
MMM
多$2.0B
$-7.9M
两年增速更快
AORT
近两年复合增速
-1.8%
损益表 — Q4 2025 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $6.0B |
| 净利润 | $2.4M | $653.0M |
| 毛利率 | 63.1% | 40.7% |
| 营业利润率 | 9.2% | 23.2% |
| 净利率 | 2.1% | 10.8% |
| 营收同比 | 19.2% | 1.3% |
| 净利润同比 | 114.7% | -41.5% |
| 每股收益（稀释后） | $0.06 | $1.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTMMM
| Q1 26 | — | $6.0B | ||
| Q4 25 | $116.0M | $6.1B | ||
| Q3 25 | $113.4M | $6.5B | ||
| Q2 25 | $113.0M | $6.3B | ||
| Q1 25 | $99.0M | $6.0B | ||
| Q4 24 | $97.3M | $6.0B | ||
| Q3 24 | $95.8M | $6.3B | ||
| Q2 24 | $98.0M | $6.3B |
净利润AORTMMM
| Q1 26 | — | $653.0M | ||
| Q4 25 | $2.4M | $577.0M | ||
| Q3 25 | $6.5M | $834.0M | ||
| Q2 25 | $1.3M | $723.0M | ||
| Q1 25 | $-505.0K | $1.1B | ||
| Q4 24 | $-16.5M | $728.0M | ||
| Q3 24 | $-2.3M | $1.4B | ||
| Q2 24 | $-2.1M | $1.1B |
毛利率AORTMMM
| Q1 26 | — | 40.7% | ||
| Q4 25 | 63.1% | 33.6% | ||
| Q3 25 | 65.6% | 41.8% | ||
| Q2 25 | 64.7% | 42.5% | ||
| Q1 25 | 64.2% | 41.6% | ||
| Q4 24 | 63.2% | 51.7% | ||
| Q3 24 | 63.7% | 42.1% | ||
| Q2 24 | 64.6% | 42.9% |
营业利润率AORTMMM
| Q1 26 | — | 23.2% | ||
| Q4 25 | 9.2% | 13.0% | ||
| Q3 25 | 11.1% | 22.2% | ||
| Q2 25 | 7.4% | 18.0% | ||
| Q1 25 | 2.2% | 20.9% | ||
| Q4 24 | 2.7% | 12.2% | ||
| Q3 24 | 4.6% | 20.9% | ||
| Q2 24 | 6.6% | 20.3% |
净利率AORTMMM
| Q1 26 | — | 10.8% | ||
| Q4 25 | 2.1% | 9.4% | ||
| Q3 25 | 5.7% | 12.8% | ||
| Q2 25 | 1.2% | 11.4% | ||
| Q1 25 | -0.5% | 18.7% | ||
| Q4 24 | -16.9% | 12.1% | ||
| Q3 24 | -2.4% | 21.8% | ||
| Q2 24 | -2.2% | 18.3% |
每股收益（稀释后）AORTMMM
| Q1 26 | — | $1.23 | ||
| Q4 25 | $0.06 | $1.07 | ||
| Q3 25 | $0.13 | $1.55 | ||
| Q2 25 | $0.03 | $1.34 | ||
| Q1 25 | $-0.01 | $2.04 | ||
| Q4 24 | $-0.40 | $1.33 | ||
| Q3 24 | $-0.05 | $2.48 | ||
| Q2 24 | $-0.05 | $2.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $3.7B |
| 总债务越低越好 | $215.1M | $10.9B |
| 股东权益账面价值 | $448.2M | $3.3B |
| 总资产 | $884.8M | $35.4B |
| 负债/权益比越低杠杆越低 | 0.48× | 3.29× |
8季度趋势，按日历期对齐
现金及短期投资AORTMMM
| Q1 26 | — | $3.7B | ||
| Q4 25 | $64.9M | — | ||
| Q3 25 | $73.4M | — | ||
| Q2 25 | $53.5M | — | ||
| Q1 25 | $37.7M | — | ||
| Q4 24 | $53.5M | — | ||
| Q3 24 | $56.2M | — | ||
| Q2 24 | $55.0M | — |
总债务AORTMMM
| Q1 26 | — | $10.9B | ||
| Q4 25 | $215.1M | $12.6B | ||
| Q3 25 | $214.9M | $12.6B | ||
| Q2 25 | $215.6M | $13.1B | ||
| Q1 25 | $314.7M | $13.5B | ||
| Q4 24 | $314.3M | $13.0B | ||
| Q3 24 | $314.0M | $13.2B | ||
| Q2 24 | $313.6M | $13.1B |
股东权益AORTMMM
| Q1 26 | — | $3.3B | ||
| Q4 25 | $448.2M | $4.7B | ||
| Q3 25 | $438.7M | $4.6B | ||
| Q2 25 | $419.9M | $4.3B | ||
| Q1 25 | $294.3M | $4.5B | ||
| Q4 24 | $276.2M | $3.8B | ||
| Q3 24 | $304.7M | $4.6B | ||
| Q2 24 | $295.1M | $3.9B |
总资产AORTMMM
| Q1 26 | — | $35.4B | ||
| Q4 25 | $884.8M | $37.7B | ||
| Q3 25 | $857.7M | $37.6B | ||
| Q2 25 | $838.4M | $38.0B | ||
| Q1 25 | $791.2M | $40.0B | ||
| Q4 24 | $789.1M | $39.9B | ||
| Q3 24 | $803.1M | $40.9B | ||
| Q2 24 | $789.5M | $43.4B |
负债/权益比AORTMMM
| Q1 26 | — | 3.29× | ||
| Q4 25 | 0.48× | 2.68× | ||
| Q3 25 | 0.49× | 2.72× | ||
| Q2 25 | 0.51× | 3.06× | ||
| Q1 25 | 1.07× | 3.02× | ||
| Q4 24 | 1.14× | 3.40× | ||
| Q3 24 | 1.03× | 2.84× | ||
| Q2 24 | 1.06× | 3.34× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | — |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $2.0B |
| 自由现金流率自由现金流/营收 | -6.9% | 33.6% |
| 资本支出强度资本支出/营收 | 23.7% | — |
| 现金转化率经营现金流/净利润 | 8.06× | — |
| 过去12个月自由现金流最近4个季度 | $839.0K | $3.7B |
8季度趋势，按日历期对齐
经营现金流AORTMMM
| Q1 26 | — | — | ||
| Q4 25 | $19.6M | $1.6B | ||
| Q3 25 | $22.3M | $1.8B | ||
| Q2 25 | $15.0M | $-954.0M | ||
| Q1 25 | $-17.0M | $-79.0M | ||
| Q4 24 | $10.1M | $1.8B | ||
| Q3 24 | $11.5M | $-1.8B | ||
| Q2 24 | $6.1M | $1.0B |
自由现金流AORTMMM
| Q1 26 | — | $2.0B | ||
| Q4 25 | $-7.9M | $1.3B | ||
| Q3 25 | $17.7M | $1.5B | ||
| Q2 25 | $11.7M | $-1.2B | ||
| Q1 25 | $-20.6M | $-315.0M | ||
| Q4 24 | $8.7M | $1.5B | ||
| Q3 24 | $7.8M | $-2.0B | ||
| Q2 24 | $3.6M | $752.0M |
自由现金流率AORTMMM
| Q1 26 | — | 33.6% | ||
| Q4 25 | -6.9% | 21.8% | ||
| Q3 25 | 15.6% | 23.6% | ||
| Q2 25 | 10.4% | -18.3% | ||
| Q1 25 | -20.8% | -5.3% | ||
| Q4 24 | 9.0% | 25.4% | ||
| Q3 24 | 8.2% | -32.3% | ||
| Q2 24 | 3.7% | 12.0% |
资本支出强度AORTMMM
| Q1 26 | — | — | ||
| Q4 25 | 23.7% | 4.0% | ||
| Q3 25 | 4.1% | 3.3% | ||
| Q2 25 | 2.9% | 3.3% | ||
| Q1 25 | 3.7% | 4.0% | ||
| Q4 24 | 1.5% | 4.8% | ||
| Q3 24 | 3.8% | 3.9% | ||
| Q2 24 | 2.6% | 4.3% |
现金转化率AORTMMM
| Q1 26 | — | — | ||
| Q4 25 | 8.06× | 2.74× | ||
| Q3 25 | 3.42× | 2.11× | ||
| Q2 25 | 11.16× | -1.32× | ||
| Q1 25 | — | -0.07× | ||
| Q4 24 | — | 2.50× | ||
| Q3 24 | — | -1.30× | ||
| Q2 24 | — | 0.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
MMM
| Safety and Industrial business segment | $2.9B | 49% |
| Transportation and Electronics business segment | $1.8B | 31% |
| Consumer business segment | $1.1B | 19% |
| Corporate | $121.0M | 2% |
